Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study

被引:11
|
作者
Park, Jin Hyun [1 ]
Choi, In Sil [1 ]
Kim, Ki Hwan [1 ]
Kim, Jin-Soo [1 ]
Lee, Kyung-Hun [2 ,3 ]
Kim, Tae-Yong [2 ,3 ]
Im, Seock-Ah [2 ,3 ]
Kim, Se Hyun [4 ]
Kim, Yu Jung [4 ]
Kim, Jee Hyun [4 ]
机构
[1] Seoul Natl Univ, Coll Med, Boramae Med Ctr, Seoul Metropolitan Govt,Dept Internal Med, 20 Boramae Ro,5 Gil, Seoul 07061, South Korea
[2] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[3] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Seongnam, South Korea
关键词
Aged; Breast neoplasms; Drug therapy; Survival; OLDER WOMEN; ADJUVANT CHEMOTHERAPY; 1ST-LINE CHEMOTHERAPY; WEEKLY PACLITAXEL; PHASE-II; AGE; SURVIVAL; TOXICITY; UNDERTREATMENT; PARTICIPATION;
D O I
10.4048/jbc.2017.20.4.368
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Currently, there is little information regarding optimal treatment for metastatic breast cancer (MBC) in elderly patients. In this retrospective study, we examined a cohort of elderly patients with MBC receiving a range of treatments, in terms of demographic and clinicopathologic characteristics, treatment patterns, and outcomes. Methods: Patients aged 65 years and older, and diagnosed with MBC between 2003 and 2015, were identified from the databases of three academic hospitals in South Korea. A total of 161 cases were eligible for inclusion. We assessed clinicopathologic features, treatment patterns, and outcomes, using the available electronic medical records. Based on age at MBC diagnosis, patients were divided into three groups: 65 to 69, 70 to 74, and >= 75 years. Results: Most patients had received active treatment according to biologic subtype as in younger patients, although frequent dose modifications were observed during chemotherapy. The median overall survival (OS) for all patients was 30.3 months; age (>= 70 years), Eastern Co-operative Oncology Group (ECOG) performance status (PS) (>= 2), triple-negative cancer, and number of metastatic sites (>= 2) were significant poor prognostic factors for OS in multivariate analyses. All types of systemic treatments according to biologic subtype conferred more prolonged OS in patients receiving treatment. Patients aged >= 75 years were more likely to have a poor ECOG PS and advanced comorbidity, and tended to receive less intensive treatments compared to the other age groups. Conclusion: Elderly patients with MBC should not be excluded from receiving standard treatments prescribed for younger patients. Future research plans for elderly patients, especially aged >= 75 years with breast cancer, should include a geriatric assessment for identifying individuals at risk for treatment-related toxicity. Overall, this analysis will provide a better understanding of this population and help guide clinical care in real-world practice.
引用
收藏
页码:368 / 377
页数:10
相关论文
共 50 条
  • [1] A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer
    Kenji Hashimoto
    Kan Yonemori
    Chikako Shimizu
    Akihiro Hirakawa
    Harukaze Yamamoto
    Makiko Ono
    Taizo Hirata
    Tsutomu Kouno
    Kenji Tamura
    Noriyuki Katsumata
    Masashi Ando
    Yasuhiro Fujiwara
    [J]. Medical Oncology, 2011, 28 : 434 - 440
  • [2] A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer
    Hashimoto, Kenji
    Yonemori, Kan
    Shimizu, Chikako
    Hirakawa, Akihiro
    Yamamoto, Harukaze
    Ono, Makiko
    Hirata, Taizo
    Kouno, Tsutomu
    Tamura, Kenji
    Katsumata, Noriyuki
    Ando, Masashi
    Fujiwara, Yasuhiro
    [J]. MEDICAL ONCOLOGY, 2011, 28 (02) : 434 - 440
  • [3] Eribulin treatment for patients with metastatic breast cancer: The United Kingdom experience-a multicenter retrospective study
    Jafri, Mariam
    Kristeleit, Hartmut
    Misra, Vivek
    Baxter, Mark
    Ahmed, Samreen
    Jegannathen, Apurna
    Jain, Ankit
    Maskell, David
    Barthakur, Urmila
    Edwards, Gwenllian
    Walter, Harriet S.
    Walshaw, Richard
    Khan, Madeha
    Borley, Annabel
    Rea, Daniel
    [J]. ONCOLOGY, 2022, : 666 - 673
  • [4] PATTERNS AND OUTCOMES OF TREATMENT IN ELDERLY PATIENTS WITH OVARIAN CANCER: A RETROSPECTIVE MONO-ISTITUTIONAL STUDY
    Nicoletto, M. O.
    Furini, L.
    Dalla Palma, M.
    Borgato, L.
    Fiduccia, P.
    Rocchetto, M.
    Nardelli, G. B.
    Gervasi, M. T.
    Zagonel, V.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 326 - 326
  • [5] Patterns of recurrence and outcomes in patients with luminal breast cancer: a retrospective study
    Li, Z. H.
    Xiong, J. P.
    Hu, P. H.
    Tu, J. H.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2017, 38 (01) : 14 - 19
  • [6] Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study
    Puskulluoglu, Mirosiawa
    Konieczna, Aleksandra
    Swiderska, Katarzyna
    Streb, Joanna
    Pieniazek, Maigorzata
    Grela-Wojewoda, Alek-sandra
    Pacholczak-Madej, Renata
    Mucha-Maiecka, Anna
    Mitus, Jerzy W.
    Szpor, Joanna
    Kunkiel, Michai
    Rudzinska, Agnieszka
    Jarzab, Michai
    Ziobro, Marek
    [J]. ACTA ONCOLOGICA, 2024, 63 : 620 - 635
  • [7] Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
    Kaufman, Peter A.
    Brufsky, Adam M.
    Mayer, Musa
    Rugo, Hope S.
    Tripathy, Debu
    Yood, Marianne Ulcickas
    Feng, Shibao
    Wang, Lisa I.
    Quah, Cheng S.
    Yardley, Denise A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (03) : 875 - 883
  • [8] Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
    Peter A. Kaufman
    Adam M. Brufsky
    Musa Mayer
    Hope S. Rugo
    Debu Tripathy
    Marianne Ulcickas Yood
    Shibao Feng
    Lisa I. Wang
    Cheng S. Quah
    Denise A. Yardley
    [J]. Breast Cancer Research and Treatment, 2012, 135 : 875 - 883
  • [9] Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
    Yizhao Xie
    Yannan Zhao
    Chengcheng Gong
    Zhanhong Chen
    Yinbin Zhang
    Yanxia Zhao
    Peng Yuan
    Sainan Hu
    Yi Li
    Xichun Hu
    Jian Zhang
    Leiping Wang
    Biyun Wang
    [J]. Scientific Reports, 9
  • [10] Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
    Xie, Yizhao
    Zhao, Yannan
    Gong, Chengcheng
    Chen, Zhanhong
    Zhang, Yinbin
    Zhao, Yanxia
    Yuan, Peng
    Hu, Sainan
    Li, Yi
    Hu, Xichun
    Zhang, Jian
    Wang, Leiping
    Wang, Biyun
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)